Literature DB >> 10969819

The effect of exogenous prostaglandin administration on tumor size and yield in Min/+ mice.

J W Wilson1, C S Potten.   

Abstract

This study set out to examine the effect of exogenous prostaglandin (PG) administration on tumor development in Min/+ mice. Mice were treated with the stable prostaglandin E2 analogue 16,16-dimethyl-PGE2 from 6-18 weeks of age. Mice were sacrificed, and tumor burden was assessed using morphometric techniques. Parameters measured were median tumor size, mean tumor size, the proportion of the area of the gastrointestinal mucosa covered with tumor, and the number of tumors per 1000 mm2 of gastrointestinal mucosa. In addition, proliferative and apoptotic indices were determined. These measurements were carried out for all regions of the small intestine (i.e., duodenum, jejunum, upper ileum, and lower ileum) and the large intestine (i.e., cecum and mid-colon/rectum). 16,16-Dimethyl-PGE2-treated animals showed a significant decrease in tumor burden (by approximately 50-70%), in comparison with those animals that were treated with vehicle alone (0.001% ethanol in 0.9% sterile saline), in all regions of the intestine (at P = 0.008 or better). This effect was contributed to by a reduction in the number of tumors (by approximately 20-50%) and a reduction in tumor size (by approximately 10-70%). An increase in tumor cell turnover was associated with this decrease in tumor burden, as determined by the changes in the levels of thymidine incorporation (significant at P = 0.003), apoptosis, and mitosis (nonsignificant).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969819

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  Multifaceted roles of PGE2 in inflammation and cancer.

Authors:  Masako Nakanishi; Daniel W Rosenberg
Journal:  Semin Immunopathol       Date:  2012-09-21       Impact factor: 9.623

2.  Loss of p21Waf1/Cip1/Sdi1 enhances intestinal stem cell survival following radiation injury.

Authors:  Robert J George; Mark A Sturmoski; Randal May; Sripathi M Sureban; Brian K Dieckgraefe; Shrikant Anant; Courtney W Houchen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-12-04       Impact factor: 4.052

3.  The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia.

Authors:  Yasmin Hernandez; John Sotolongo; Keith Breglio; Daisy Conduah; Anli Chen; Ruliang Xu; David Hsu; Ryan Ungaro; Lory A Hayes; Cristhine Pastorini; Maria T Abreu; Masayuki Fukata
Journal:  BMC Gastroenterol       Date:  2010-07-16       Impact factor: 3.067

4.  Inhibition of human glioma cell growth by a PHS-2 inhibitor, NS398, and a prostaglandin E receptor subtype EP1-selective antagonist, SC51089.

Authors:  Muneaki Matsuo; Nobuyuki Yoshida; Masahumi Zaitsu; Kiyohisa Ishii; Yuhei Hamasaki
Journal:  J Neurooncol       Date:  2004-02       Impact factor: 4.130

5.  Role of cAMP in the promotion of colorectal cancer cell growth by prostaglandin E2.

Authors:  Ivonne Löffler; Michael Grün; Frank D Böhmer; Ignacio Rubio
Journal:  BMC Cancer       Date:  2008-12-19       Impact factor: 4.430

6.  Relationship between tumour PTEN/Akt/COX-2 expression, inflammatory response and survival in patients with colorectal cancer.

Authors:  Antonia K Roseweir; Arfon G M T Powell; Lindsay Bennett; Hester C Van Wyk; James Park; Donald C McMillan; Paul G Horgan; Joanne Edwards
Journal:  Oncotarget       Date:  2016-10-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.